Hisamitsu Pharmaceutical Co Inc represents values of innovation, quality, and commitment to improving healthcare. With a strong corporate philosophy, the company aims to provide effective and safe pharmaceutical products to enhance people's well-being. Its focus on research and development has led to breakthroughs in drug delivery systems, including its flagship product, the PAIN PATCH. By continuously investing in technological advancements and maintaining high standards, Hisamitsu Pharmaceutical Co Inc sets itself apart as a trusted and reputable company in the pharmaceutical industry.

Hisamitsu Pharmaceutical Co Inc is primarily present in Japan, where it is headquartered and has a strong market presence. As a leading pharmaceutical company, Hisamitsu has expanded its operations internationally and is also present in various countries and regions worldwide. Some of the key markets where Hisamitsu Pharmaceutical Co Inc operates include the United States, Europe, China, Asia-Pacific, and other regions. With its diverse range of healthcare products and global reach, Hisamitsu Pharmaceutical Co Inc continues to contribute to the well-being of people across different countries and regions.

Some significant milestones achieved by Hisamitsu Pharmaceutical Co Inc include the development of the world's first topical patch for pain relief, the launch of their flagship product Salonpas, which has become a globally recognized brand, and their continuous research and development efforts in pharmaceutical technology. Additionally, Hisamitsu Pharmaceutical Co Inc has expanded its global presence through strategic partnerships and acquisitions, strengthening its position in the international market. Their commitment to innovation and high-quality healthcare products has garnered them numerous accolades and recognition within the industry.

Hisamitsu Pharmaceutical Co Inc is a renowned Japanese company with a rich history and background in the pharmaceutical industry. Founded in 1847, Hisamitsu has been dedicated to providing innovative healthcare solutions to improve people's lives. With a focus on the development and manufacturing of pharmaceutical products, the company has established itself as a leader in transdermal drug delivery systems. Hisamitsu Pharmaceutical Co Inc has grown into a global entity, operating in various countries and expanding its product portfolio to include a wide range of over-the-counter medicines, medical devices, and prescription drugs. With a commitment to research, quality, and customer satisfaction, Hisamitsu continues to contribute to the advancement of healthcare worldwide.

The main competitors of Hisamitsu Pharmaceutical Co Inc in the market include large pharmaceutical companies such as Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, and Astellas Pharma Inc. Additionally, other competitors may include global pharmaceutical companies like Pfizer Inc. and Novartis AG. These companies compete with Hisamitsu Pharmaceutical Co Inc in various therapeutic areas, including pain management and patches.

Hisamitsu Pharmaceutical Co Inc is primarily active in the pharmaceutical industry.

The business model of Hisamitsu Pharmaceutical Co Inc focuses on the development, manufacturing, and sales of pharmaceutical products. As a leading Japanese pharmaceutical company, Hisamitsu Pharmaceutical specializes in producing transdermal therapeutic patches, such as the popular brand Salonpas. By utilizing innovative drug delivery systems and advanced research, the company aims to provide effective and convenient solutions for pain relief and healthcare. With a strong emphasis on quality and customer satisfaction, Hisamitsu Pharmaceutical continues to expand its product portfolio and global presence, addressing the diverse healthcare needs of individuals worldwide.

مُعامل القيمة السوقية إلى الأرباح لـ Hisamitsu Pharmaceutical Co هو ٢٢٫٠٨.

مُعامِل القيمة إلى المبيعات Hisamitsu Pharmaceutical Co هو ٢٫١٨.

نقاط جودة AlleAktien لـ Hisamitsu Pharmaceutical Co هي 5/10.

Hisamitsu Pharmaceutical Co الإيرادات هي ١٤١٫٧١ مليارات JPY.

صافي الربح Hisamitsu Pharmaceutical Co هو ١٣٫٩٧ مليارات JPY.

Hisamitsu Pharmaceutical Co Inc is a Japanese company specializing in the manufacture and sale of pharmaceutical products. It has a wide range of medicines for the treatment of musculoskeletal, respiratory, cardiovascular, and skin disorders. The business model of Hisamitsu is based on researching and developing new drugs, as well as marketing and distributing these products globally. The company conducts research and development worldwide to continuously expand its product range and meet the needs of consumers. Hisamitsu's medicines are divided into different categories, including pain relief, dermatology, gastroenterology, and respiratory diseases. In the pain relief category, the company offers various products such as pain patches, ointments, and creams used to relieve joint pain, muscle soreness, and other pain symptoms. In the dermatology category, Hisamitsu produces innovative medications for the treatment of skin diseases such as acne, eczema, and dermatitis. In the gastroenterology category, Hisamitsu offers medications for the treatment of gastrointestinal disorders such as heartburn, acid reflux, and digestive disorders. In the respiratory diseases category, the company provides products for the treatment of conditions like asthma, chronic obstructive pulmonary disease (COPD), and seasonal allergic rhinitis. Hisamitsu has a wide distribution network and sells its products in over 60 countries worldwide. It collaborates with various partners, retailers, and health organizations to ensure that its products are available in every region globally. The company also operates an extensive research and development department to further develop its innovative medications. It invests significant resources in the search for new active ingredients that can be used to treat conditions that have not been addressed previously. Hisamitsu's business model also includes collaboration with other companies to develop and jointly market innovative products. Collaborating with other manufacturers allows Hisamitsu to diversify its product range and reach a broader customer base. Overall, Hisamitsu's business model is based on a combination of research and development, distribution partnerships, and a strong presence in the global market. With a wide range of innovative pharmaceutical products and a strong commitment to research and development of new medications, Hisamitsu Pharmaceutical Co Inc has established a leading position in the pharmaceutical industry and will play an important role in improving the health and well-being of people worldwide in the future.

يوزع Hisamitsu Pharmaceutical Co أرباحًا قدرها ٤٢٫٢٥ JPY من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Hisamitsu Pharmaceutical Co في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـHisamitsu Pharmaceutical Co هو JP3784600003.

رمز WKN لـ Hisamitsu Pharmaceutical Co هو 864341.

الرمز المُختصر لـ Hisamitsu Pharmaceutical Co هو 4530.T.

خلال آخر 12 شهراً، دفعت Hisamitsu Pharmaceutical Co توزيعات أرباح بقيمة ٤٤٫٥٠ JPY . وهذا يعادل عائد توزيعات أرباح يقارب ١٫١١ %. ومن المتوقع أن تدفع Hisamitsu Pharmaceutical Co خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ٤٥٫٤٢ JPY.

نسبة توزيعات الأرباح الحالية لـ Hisamitsu Pharmaceutical Co هي ١٫١١ %.

Hisamitsu Pharmaceutical Co يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر سبتمبر, مارس, سبتمبر, مارس.

Hisamitsu Pharmaceutical Co دفعت توزيعات الأرباح كل عام خلال الـ23 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ٤٥٫٤٢ JPY. وهذا يعادل عائد توزيعات أرباح قدره ١٫١٣ %.

Hisamitsu Pharmaceutical Co يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٢ JPY من Hisamitsu Pharmaceutical Co المُعلن عنها في ١‏/١١‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٩‏/٨‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١‏/١١‏/٢٠٢٤.

في العام 2023، وزعت Hisamitsu Pharmaceutical Co ٤٢٫٧٥ JPY كأرباح أسهم.

يتم توزيع أرباح Hisamitsu Pharmaceutical Co بالعملة JPY.